Lundbeck's Vyepti Launch In US Disappoints In First Half

Sales of H. Lundbeck A/S's new migraine prevention therapy, Vyepti (eptinezumab-jjmr), launched in the US in April, were significantly impacted by the COVID-19 pandemic, achieving revenues of only DKK14m ($2.2m) in the first half. But sales of its top four products drove the company’s total revenues up by 5% , with the CNS-focused Danish firm raising its earnings guidance for the year.

It was always going to be a challenge to launch a new product during the pandemic, and so it turned out, although Lundbeck is confident about Vyepti’s future promise: “Despite being significantly impacted by a lower number of medical procedures due to COVID-19, we remain very confident with Vyepti’s ability to deliver on its promise based on how it has benefited patients,” said CEO Deborah Dunsire